688136 科兴制药
已收盘 03-16 15:00:01
资讯
新帖
简况
科兴制药（688136）披露股份回购进展及实施结果暨股份变动公告，3月3日股价下跌4.18%
证券之星 · 03-03
科兴制药（688136）披露股份回购进展及实施结果暨股份变动公告，3月3日股价下跌4.18%
科兴制药最新公告：GB19注射液皮肤型红斑狼疮适应症获得药物临床试验批准
证券之星 · 03-03
科兴制药最新公告：GB19注射液皮肤型红斑狼疮适应症获得药物临床试验批准
科兴制药2025年净利增超4倍，年前已启动赴港上市
齐鲁晚报 · 03-02
科兴制药2025年净利增超4倍，年前已启动赴港上市
科兴制药发布2025年度业绩快报，盈利1.594亿元
证券之星 · 02-27
科兴制药发布2025年度业绩快报，盈利1.594亿元
科兴制药（688136）披露GB19注射液获临床试验批准通知书，2月25日股价下跌0.58%
证券之星 · 02-25
科兴制药（688136）披露GB19注射液获临床试验批准通知书，2月25日股价下跌0.58%
科兴制药H股上市进程及创新药管线进展引关注
经济观察网 · 02-12
科兴制药H股上市进程及创新药管线进展引关注
每周股票复盘：科兴制药（688136）回购股份131.9万股
证券之星 · 02-08
每周股票复盘：科兴制药（688136）回购股份131.9万股
科兴制药（688136）披露以集中竞价交易方式回购公司股份的进展公告，2月3日股价上涨1.0%
证券之星 · 02-03
科兴制药（688136）披露以集中竞价交易方式回购公司股份的进展公告，2月3日股价上涨1.0%
股市必读：科兴制药（688136）预计2025年全年归属净利润盈利1.35亿元至1.75亿元
证券之星 · 02-02
股市必读：科兴制药（688136）预计2025年全年归属净利润盈利1.35亿元至1.75亿元
每周股票复盘：科兴制药（688136）2025年净利预增328.83%至455.89%
证券之星 · 02-01
每周股票复盘：科兴制药（688136）2025年净利预增328.83%至455.89%
科兴制药：预计2025年全年归属净利润盈利1.35亿元至1.75亿元
证券之星 · 01-30
科兴制药：预计2025年全年归属净利润盈利1.35亿元至1.75亿元
每周股票复盘：科兴制药（688136）已回购131.9万股支付近4924万元
证券之星 · 01-11
每周股票复盘：科兴制药（688136）已回购131.9万股支付近4924万元
科兴制药（688136）披露以集中竞价交易方式回购公司股份的进展公告，01月05日股价上涨5.34%
证券之星 · 01-05
科兴制药（688136）披露以集中竞价交易方式回购公司股份的进展公告，01月05日股价上涨5.34%
每周股票复盘：科兴制药（688136）募投资金调整至研发临床投入
证券之星 · 2025-12-28
每周股票复盘：科兴制药（688136）募投资金调整至研发临床投入
科兴制药（688136）披露拟变更部分募集资金用途，12月23日股价上涨1.36%
证券之星 · 2025-12-23
科兴制药（688136）披露拟变更部分募集资金用途，12月23日股价上涨1.36%
科兴制药（688136）披露变更部分募集资金用途及部分募投项目延期公告，12月15日股价下跌1.43%
证券之星 · 2025-12-15
科兴制药（688136）披露变更部分募集资金用途及部分募投项目延期公告，12月15日股价下跌1.43%
科兴制药(688136.SH)：眼科制剂GB10注射液获得药物临床试验批准
智通财经 · 2025-12-08
科兴制药(688136.SH)：眼科制剂GB10注射液获得药物临床试验批准
科兴制药（688136）披露以集中竞价交易方式回购公司股份的进展公告，12月02日股价下跌1.95%
证券之星 · 2025-12-02
科兴制药（688136）披露以集中竞价交易方式回购公司股份的进展公告，12月02日股价下跌1.95%
科兴制药（688136）披露股东询价转让结果暨持股5%以上股东权益变动触及5%整数倍提示，11月20日股价上涨0.6%
证券之星 · 2025-11-20
科兴制药（688136）披露股东询价转让结果暨持股5%以上股东权益变动触及5%整数倍提示，11月20日股价上涨0.6%
科兴制药（688136）披露股东询价转让定价情况提示性公告，11月18日股价下跌0.4%
证券之星 · 2025-11-18
科兴制药（688136）披露股东询价转让定价情况提示性公告，11月18日股价下跌0.4%
加载更多
公司概况
公司名称：
科兴生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-12-14
主营业务：
科兴生物制药股份有限公司的主营业务是重组蛋白药物和微生态制剂的研发、生产、销售。公司的主要产品是依普定、赛若金、白特喜、常乐康。
发行价格：
22.33
{"stockData":{"symbol":"688136","market":"SH","secType":"STK","nameCN":"科兴制药","latestPrice":29.88,"timestamp":1773644401000,"preClose":29.49,"halted":0,"volume":1477598,"delay":0,"changeRate":0.0132,"floatShares":200999999,"shares":200999999,"eps":0.624,"marketStatus":"已收盘","change":0.39,"latestTime":"03-16 15:00:01","open":29.21,"high":30.07,"low":29.21,"amount":43937100,"amplitude":0.0292,"askPrice":29.88,"askSize":15,"bidPrice":29.87,"bidSize":11,"shortable":0,"etf":0,"ttmEps":0.624,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773711000000},"marketStatusCode":5,"adr":0,"adjPreClose":29.49,"symbolType":"stock_kcb","openAndCloseTimeList":[[1773624600000,1773631800000],[1773637200000,1773644400000]],"highLimit":32.44,"lowLimit":26.54,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201257250,"isCdr":false,"pbRate":3.51,"roa":"--","peRate":47.884615,"roe":"6.66%","epsLYR":0.16,"committee":0.374408,"marketValue":6014000000,"turnoverRate":0.0073,"status":0,"afterMarket":{"amount":0,"volume":0,"close":29.88,"buyVolume":0,"sellVolume":0,"time":1773646437558,"indexStatus":"已收盘 03-16 15:30:00","preClose":29.49},"floatMarketCap":6014000000},"requestUrl":"/m/hq/s/688136","defaultTab":"news","newsList":[{"id":"2616739329","title":"科兴制药（688136）披露股份回购进展及实施结果暨股份变动公告，3月3日股价下跌4.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616739329","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616739329?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:50","pubTimestamp":1772549427,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，科兴制药报收于28.63元，较前一交易日下跌4.18%，最新总市值为57.62亿元。近日，科兴生物制药股份有限公司发布《关于股份回购进展及实施结果暨股份变动的公告》。本次回购股份用于员工持股计划或股权激励，回购方案已实施完毕，未对公司经营、财务状况及股权分布产生重大影响。回购股份存放于专用证券账户，不享有表决权、利润分配等股东权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300044716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2616462843","title":"科兴制药最新公告：GB19注射液皮肤型红斑狼疮适应症获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616462843","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616462843?lang=zh_cn&edition=full","pubTime":"2026-03-03 18:40","pubTimestamp":1772534409,"startTime":"0","endTime":"0","summary":"科兴制药(688136.SH)公告称，公司全资子公司深圳科兴药业有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意创新药GB19注射液开展皮肤型红斑狼疮（CLE）适应症的临床试验。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300034440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2616336085","title":"科兴制药2025年净利增超4倍，年前已启动赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2616336085","media":"齐鲁晚报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616336085?lang=zh_cn&edition=full","pubTime":"2026-03-02 19:29","pubTimestamp":1772450940,"startTime":"0","endTime":"0","summary":"近日，科兴制药（688136.SH）披露的业绩快报显示，2025年，公司实现营业收入15.41亿元，同比增长9.54%；归母净利润1.59亿元，同比大增406.47%；扣非归母净利润为5970.62万元，同比增长69.36 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260302/c675022779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2614920839","title":"科兴制药发布2025年度业绩快报，盈利1.594亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614920839","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614920839?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:51","pubTimestamp":1772185887,"startTime":"0","endTime":"0","summary":"证券之星消息，科兴制药近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利1.594亿元，同比增长406.47%。业绩快报公告中对经营业绩和财务状况情况的说明：（一）报告期的经营情况、财务状况及影响经营业绩的主要因素1.报告期的经营情况、财务状况报告期内，公司实现营业收入 154,115.64 万元，同比增长 9.54%。报告期内非经常性损益金额较上年同期增加主要系公司持有的私募基金公允价值变动及处置下属子公司取得收益所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700030186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2614103519","title":"科兴制药（688136）披露GB19注射液获临床试验批准通知书，2月25日股价下跌0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614103519","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614103519?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:46","pubTimestamp":1772030772,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，科兴制药报收于30.59元，较前一交易日下跌0.58%，最新总市值为61.56亿元。该股当日开盘30.61元，最高30.85元，最低30.51元，成交额达6404.21万元，换手率为1.04%。近日，科兴生物制药股份有限公司全资子公司深圳科兴药业有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意其自主研发的GB19注射液开展系统性红斑狼疮适应症的临床试验。本次获批对公司近期财务状况和经营业绩无重大影响，后续研发及审批存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2610029924","title":"科兴制药H股上市进程及创新药管线进展引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2610029924","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610029924?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:04","pubTimestamp":1770905040,"startTime":"0","endTime":"0","summary":"经济观察网 科兴生物制药股份有限公司近期在H股上市进程、创新药管线关键进展及海外市场拓展等方面有动态更新。高管变动科兴制药于2025年11月向港交所主板提交H股上市申请，后续需关注港交 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260212/c674779084.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260212/c674779084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688136","BK0239","159992"],"gpt_icon":0},{"id":"2609523052","title":"每周股票复盘：科兴制药（688136）回购股份131.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609523052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609523052?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:38","pubTimestamp":1770485892,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，科兴制药报收于31.66元，较上周的32.55元下跌2.73%。本周，科兴制药2月2日盘中最高价报32.57元。本周关注点公司公告汇总：科兴制药累计回购股份1,319,333股，占总股本0.66%。本次回购股份拟用于员工持股计划或股权激励，回购期限为2025年3月17日至2026年3月16日，回购金额预计为3,000万元至6,000万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2608774908","title":"科兴制药（688136）披露以集中竞价交易方式回购公司股份的进展公告，2月3日股价上涨1.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608774908","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608774908?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:35","pubTimestamp":1770129317,"startTime":"0","endTime":"0","summary":"近日，科兴生物制药股份有限公司发布《关于以集中竞价交易方式回购公司股份的进展公告》。公告显示，公司自2025年3月17日至2026年1月31日，通过集中竞价交易方式累计回购股份1,319,333股，占公司总股本的0.66%，已支付资金总额为4,924.18万元，回购价格区间为23.14元/股至43.50元/股。本次回购股份拟用于员工持股计划或股权激励，回购期限为2025年3月17日至2026年3月16日，回购金额预计为3,000万元至6,000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300043334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2608881280","title":"股市必读：科兴制药（688136）预计2025年全年归属净利润盈利1.35亿元至1.75亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608881280","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608881280?lang=zh_cn&edition=full","pubTime":"2026-02-02 04:52","pubTimestamp":1769979129,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，科兴制药报收于32.55元，下跌0.15%，换手率1.18%，成交量2.37万手，成交额7649.3万元。业绩披露要点业绩预告科兴制药发布业绩预告，预计2025年全年归属净利润盈利1.35亿元至1.75亿元。公司公告汇总2025年年度业绩预告科兴生物制药股份有限公司预计2025年年度实现归属于母公司所有者的净利润为13,500万元至17,500万元，与上年同期相比增加328.83%至455.89%；扣除非经常性损益后的净利润为5,000万元至7,000万元，同比增长41.83%至98.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136"],"gpt_icon":0},{"id":"2608070595","title":"每周股票复盘：科兴制药（688136）2025年净利预增328.83%至455.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070595","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070595?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:59","pubTimestamp":1769889548,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，科兴制药报收于32.55元，较上周的34.22元下跌4.88%。本周，科兴制药1月27日盘中最高价报36.1元。科兴制药当前最新总市值65.51亿元，在生物制品板块市值排名37/51，在两市A股市值排名2854/5184。本周关注点业绩披露要点：科兴制药预计2025年净利增长328.83%至455.89%。科兴制药发布业绩预告，预计2025年全年归属净利润盈利1.35亿元至1.75亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2607501634","title":"科兴制药：预计2025年全年归属净利润盈利1.35亿元至1.75亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607501634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607501634?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:02","pubTimestamp":1769767341,"startTime":"0","endTime":"0","summary":"证券之星消息，科兴制药发布业绩预告，预计2025年全年归属净利润盈利1.35亿元至1.75亿元。科兴制药2025年三季报显示，前三季度公司主营收入11.48亿元，同比上升10.54%；归母净利润1.11亿元，同比上升547.7%；扣非净利润7044.66万元，同比上升190.65%；其中2025年第三季度，公司单季度主营收入4.47亿元，同比上升60.65%；单季度归母净利润3091.85万元，同比上升483.27%；单季度扣非净利润2516.75万元，同比上升829.53%；负债率49.69%，投资收益2718.72万元，财务费用2315.98万元，毛利率63.54%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000032212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136"],"gpt_icon":0},{"id":"2602536914","title":"每周股票复盘：科兴制药（688136）已回购131.9万股支付近4924万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536914?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:58","pubTimestamp":1768075088,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，科兴制药报收于35.35元，较上周的31.67元上涨11.62%。本周，科兴制药1月9日盘中最高价报35.42元。科兴制药当前最新总市值71.14亿元，在生物制品板块市值排名38/51，在两市A股市值排名2681/5182。截至2025年12月31日，已累计回购1,319,333股，占总股本0.66%，回购价格区间为23.14元/股至43.50元/股，支付资金总额4,924.18万元。公司已按规定调整回购价格上限。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2601007373","title":"科兴制药（688136）披露以集中竞价交易方式回购公司股份的进展公告，01月05日股价上涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601007373","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601007373?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:47","pubTimestamp":1767606457,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，科兴制药报收于33.36元，较前一交易日上涨5.34%，最新总市值为67.14亿元。该股当日开盘31.61元，最高33.38元，最低31.61元，成交额达1.75亿元，换手率为2.66%。公司近日发布公告称，科兴生物制药股份有限公司于2025年3月17日召开董事会，审议通过回购股份方案，拟使用自有资金及专项贷款3,000万元至6,000万元，通过集中竞价交易方式回购公司股份，用于员工持股计划或股权激励。公司已按规定调整回购价格上限。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500026236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2594247993","title":"每周股票复盘：科兴制药（688136）募投资金调整至研发临床投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2594247993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594247993?lang=zh_cn&edition=full","pubTime":"2025-12-28 05:09","pubTimestamp":1766869750,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，科兴制药报收于32.12元，较上周的32.3元下跌0.56%。本周，科兴制药12月23日盘中最高价报33.1元。科兴制药当前最新总市值64.64亿元，在生物制品板块市值排名36/51，在两市A股市值排名2758/5178。本周关注点公司公告汇总：拟变更部分募集资金用途，将10,915.22万元及利息收入、理财收益1,586.78万元用于研发中心升级建设项目的临床试验投入。公司公告汇总：拟续聘致同会计师事务所为2025年度审计机构，审计费用合计130.00万元，与2024年度持平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2593749618","title":"科兴制药（688136）披露拟变更部分募集资金用途，12月23日股价上涨1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593749618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593749618?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:58","pubTimestamp":1766483890,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，科兴制药报收于32.75元，较前一交易日上涨1.36%，最新总市值为65.91亿元。该股当日开盘32.3元，最高33.1元，最低32.03元，成交额达8019.64万元，换手率为1.23%。同时，公司拟续聘致同会计师事务所为2025年度审计机构，审计费用合计130.00万元，较2024年度无变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300029287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"gpt_icon":0},{"id":"2591426116","title":"科兴制药（688136）披露变更部分募集资金用途及部分募投项目延期公告，12月15日股价下跌1.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591426116","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591426116?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:26","pubTimestamp":1765808817,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，科兴制药报收于32.5元，较前一交易日下跌1.43%，最新总市值为65.41亿元。该股当日开盘32.79元，最高32.91元，最低32.41元，成交额达3674.97万元，换手率为0.56%。公司近日发布公告称，将于2025年12月31日召开2025年第三次临时股东会，会议将审议《关于变更部分募集资金用途及部分募投项目延期的议案》和《关于续聘2025年度审计机构的议案》。其中，《关于变更部分募集资金用途及部分募投项目延期的议案》受到市场关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500035954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2589346843","title":"科兴制药(688136.SH)：眼科制剂GB10注射液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589346843","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589346843?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:55","pubTimestamp":1765191340,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科兴制药 发布公告，近日，公司全资子公司深圳科兴药业有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，国家药监局批准同意深圳科兴开展“GB10注射液”的临床试验。GB10注射液是深圳科兴自主研发、拥有全球知识产权的抗VEGF/Ang-2双靶点抗体高浓度眼科专用蛋白药物制剂。GB10注射液浓度达到140mg/mL，可减少注射体积或提高给药量，延长给药周期，预期实现每4个月给药一次，极大提高患者依从性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科兴制药(688136.SH)：眼科制剂GB10注射液获得药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2588051892","title":"科兴制药（688136）披露以集中竞价交易方式回购公司股份的进展公告，12月02日股价下跌1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588051892","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588051892?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:29","pubTimestamp":1764685746,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，科兴制药报收于32.63元，较前一交易日下跌1.95%，最新总市值为65.67亿元。近日，科兴制药发布关于以集中竞价交易方式回购公司股份的进展公告。公告显示，截至2025年11月30日，公司通过集中竞价交易方式累计回购股份1,319,333股，占公司总股本的0.66%，已支付资金总额4,924.18万元，回购价格区间为23.14元/股至43.50元/股。本次回购股份拟用于员工持股计划或股权激励，回购期限为2025年3月17日至2026年3月16日，预计回购金额为3,000万元至6,000万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200040001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2584309031","title":"科兴制药（688136）披露股东询价转让结果暨持股5%以上股东权益变动触及5%整数倍提示，11月20日股价上涨0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584309031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584309031?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:27","pubTimestamp":1763648842,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，科兴制药报收于33.7元，较前一交易日上涨0.6%，最新总市值为67.82亿元。近日，科兴制药发布《股东询价转让结果报告书暨持股5%以上股东权益变动触及5%整数倍的提示性公告》。本次转让后，科益医药及其一致行动人邓学勤合计持股比例由55.38%降至50.38%，触及5%整数倍。转让方为公司控股股东，本次转让不会导致公司控制权变更。中国国际金融股份有限公司对本次转让出具核查意见，确认转让过程合法合规。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"gpt_icon":0},{"id":"2584933913","title":"科兴制药（688136）披露股东询价转让定价情况提示性公告，11月18日股价下跌0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584933913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584933913?lang=zh_cn&edition=full","pubTime":"2025-11-18 17:57","pubTimestamp":1763459841,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，科兴制药报收于34.45元，较前一交易日下跌0.4%，最新总市值为69.33亿元。该股当日开盘34.4元，最高34.85元，最低34.18元，成交额达6579.93万元，换手率为0.95%。公司于近日发布股东询价转让定价情况提示性公告。参与报价及申购的机构投资者共24家，有效认购股份数量为14,877,000股，有效认购倍数为1.48倍。本次询价转让拟转让股份已获全额认购，初步确定受让方为12家机构投资者，拟受让股份总数为10,062,800股。本次转让不涉及公司控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800027791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773700184813,"stockEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0106},{"period":"3month","weight":-0.0601},{"period":"6month","weight":-0.2793},{"period":"1year","weight":0.4712},{"period":"ytd","weight":-0.0565}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.068},{"period":"6month","weight":0.0538},{"period":"1year","weight":0.1945},{"period":"ytd","weight":0.0292}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"科兴生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11768人(较上一季度增加25.03%)","perCapita":"17102股","listingDate":"2020-12-14","address":"山东省济南市章丘区埠村街道创业路2666号","registeredCapital":"20125万元","survey":" 科兴生物制药股份有限公司的主营业务是重组蛋白药物和微生态制剂的研发、生产、销售。公司的主要产品是依普定、赛若金、白特喜、常乐康。","listedPrice":22.33},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科兴制药(688136)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科兴制药(688136)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科兴制药,688136,科兴制药股票,科兴制药股票老虎,科兴制药股票老虎国际,科兴制药行情,科兴制药股票行情,科兴制药股价,科兴制药股市,科兴制药股票价格,科兴制药股票交易,科兴制药股票购买,科兴制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科兴制药(688136)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科兴制药(688136)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}